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The ~9, integrin VLA-4 is expressed on practically all leukocytes, except on mature granulocytes. Here we show that in vitro treatment of monocytic 
cells with phorbol-12-myristate-13-acetate (PMA) leads to a selective decrease in the VLA-4 u-chain expression, both at the RNA and protein level. 
Meanwhile the expression of/?, and that of a,, another a-chain associating with& was se-en to increase. The decrease of a, expression was restricted 
to monocytic cells, and was not observed on other VLAll-positive cells tested (MOLT-4 T cells and HOS sarcoma cells). The down-regulation 
of the VLA-4 u-chain was followed by a decreased binding capacity of the cells to recombinant VCAM-1. This data indicates that while previous 
findings show that the integrindependent adhesion may rapidly be regulated by altering the avidity of the interacting molecules, their quantitative 
modulation also has a clear impact on adhesion. 
Integrin; VLA-4; VCAM-1; Adhesion 
1. PRODUCTION 
Leukocytes circulating in the blood extravasate 
through the endothelium after first adhering to endothe- 
lial cells. This adherence is mediated by the interaction 
between adhesion molecules on endothelial cells and 
their counterpart ligands on leukocytes. Several differ- 
ent leukocyte molecules, with both carbohydrate and 
protein recognition epitopes, are involved in extravasa- 
tion [l-4]. VLA-4 is a leukocyte-adhesion molecule that, 
among a few other ligands for endothelial adhesion 
molecules, belongs to the family of integrins [S]. 
protein level. The decreased expression of the q-chain 
was linked to a decrease in the binding of THP-1 cells 
to recombinant soluble VCAM-1 fixed on microtiter 
plates. This finding might have implications in the ex- 
travasation (metastasis) of monocytic leukemias and in- 
itiation of inflammatory and arteriosclerotic lesions. 
2. MATERIALS AND METHODS 
2.1. Materials 
~~0~~ all members of the #?1 integrin family are 
involved in cell-extracellular matrix interactions, VLA- 
4 is the only member of the family participating in var- 
ious cell-cell adhesion-dependent events [6]. VLA+ex- 
pressing T and B lymphocytes, monocytes, eosinophils, 
basophils and natural killer cells (NK) are able to ad- 
here to the endothelium through recognition of their 
counter receptor, the vascular cell adhesion molecule-l 
(VCAM-1) [7-121. 
Regulation of VLA4 has mainly been studied in lym- 
phocytes and very little is known of its Egulation in 
monocytic cells. We have studied VL&# expression on 
THP-1 and HL-60 leukemia cell lines. Activation of these 
cells with a protein kinase C stimulator, phorbol-myristate 
acetate (PMA), led to a significant decrease in VLA4 
a-chain expression in these cells, both at the RNA and 
The monocytic cell tines, THP-1 and HL-60, the human osteosar- 
coma, HOS, and a T cell line, MOLT4, were obtained from ATCC 
and cultured in RPM1 su~l~~~ with 10% FCS and antibiotics. 
PMA was obtained from Sigma (St. Louis, MO}. Recombinant IFN-y 
(2.5 x 10’ U/m& and IL-1 (3 x 10’ U/mg) were generous gifts from Dr. 
C.W. Reynolds, National Cancer Institute (Frederick, MD). Reoom- 
binant TNFu (2.0 x 10’ U/mg) was purchased from Boehringer 
(Mannheim, Germany). Recombinant soluble (rs) VCAM-1 was a 
kind gift from Dr. Roy Lobb, Biogen Inc., Cambridge, MA, USA [13]. 
[32P]dCTP was purchased from Amersham (England). The monoclo- 
nal antibody, anti-a, (clone HP1/2) was a kind gift from Dr. Roy 
Lobb, Biogen Inc. The monoclonal anti-VCAM-1 antibody (4B9) was 
a kind gift from Dr. John Harlan, Seattle. The anti-p, (clone K20), 
antiXD18 (clone IOT18) and anti-ICAM- (clone 84HlO) antibodies 
were obtained from Immunotech (Marseille, France). The secondary 
antibody for flow cytometry was the fluoresce&conjugated F(ab’)2 
fragment of rabbit i~~o~ob~ms to mouse ~m~oglob~ins pur- 
chased from Dakopatts s/s (Glostrup, Demnark). 
2.2. Flow c~toF?letry 
*Corresponding author. Fax: (358) (0) 434 6382. 
Abbreviations: VLA-4, very late activation antigen; VCAM-1, vascular 
cell adhesion molecule 1; ICAM-1, intercellular adhesion molecule-l. 
1 x 106 cells were incubated with antibody diluted with washing 
buffer (0.2% FCS/PBS) at 4’C for 30 min. The cells were then washed 
twice with washing but&r and were incubated with the fluorescein- 
labeled secondary antibody as above. After two washings the cells 
were suspended in 3% PFAiPBS and analyzed in a Beckton Dickinson 
FACSCAN analyzer. The results are expressed as a mean fluorescence 
index (MFI). For negative controls the cells were treated with second- 
ary antibody only. 
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2.3. Northern blotting seen at PMA concentrations exceeding 0. 
Total RNA was extracted according to standard protocols. 15 pug 
of RNA was transferred to a nylon filter and hybridized with 
[‘2P]dCTP-labelled a., and B, probes. As a probe for detecting human 
VLA-4 achain mRNA, we used a PCR product including bases 
2,237-2,609 in the VLA-4 o-chain gene. In the PCR reaction we used 
cDNA of THP-1 cells and the amplification was carried out in 1,000 
~1 Taq DNA polymerase buffer @omega) in the presence of 1~1 of 
primers, ATGTGAGCTCACTCAGA and CAAAGTGG- 
CATTCTCCAG, 200 PM of each dNTP and 10 ~1 of Tag DNA 
polymerase (Promega). The reaction was carried out for 30 cycles 
(denaturation at 93°C for 1 min, annealing at 54’C for 1 min, polym- 
erization at 72°C for 2 min) and it yielded a single 372-bp long ampli- 
fied product. The DNA fragment was purified in-gel and was analyzed 
by cutting with SphI, DraI and KpnI which revealed restriction sites 
corresponding to restriction sites inside bases between 2,237-2,609 of 
VLA-ct., gene. The B, probe was purchased from Telios Co. (La Jolla, 
CA, USA). Actin was used as a loading control probe. After washings 
the filters were exposed to X-ray tihn. The fihns were scanned with a 
densitometer and the results are given as relative RNA levels (cor- 
rected for the amount of RNA loaded in the gels). 
2.4. Adhesion assay 
Microtiter plates were coated with recombinant soluble VCAM-1 
(0.5 ,@well) overnight at 4°C. Plates were blocked with 1% BSA in 
PBS for 1 h at room temperature, the cells were added and allowed 
to adhere for 10 min. The number of adherent cells was quantified by 
determining the number of adhered cells in 10 high-power microscopic 
fields. For antibody inhibitions the cells were preincubated with anti- 
a, antibody (10 &ml) for 30 min at room temperature or the plates 
were incubated with anti-VCAM-1 antibody (10 pg/ml) for 30 min at 
room temperature and the adhesion assay was performed as above. 
For negative controls the cells were treated with anti-CD18 antibody 
or the plates with anti-ICAM- antibody. Background binding was 
determined from plates treated with BSA only. 
being optimal (not shown). Furthermore, the surface 
expression of the /3,-chain was simultaneously in- 
creased. The decrease in a4 expression, as well as the 
increase in the p1 expression, was already observed after 
a 24 h stimulation, but progressed steadily at least up 
to 72 h (data not shown). The effects were, however, 
more pronounced in THP-1 cells, where the initial MFI 
for anti-a4 monoclonal antibody was higher than for 
HL-60 cells (from MFI 74 to 23, and from 38 to 22 for 
THP-1 and HL-60 cells, respectively). Further experi- 
ments were therefore performed using this cell line. The 
&chain of VLA4 associates with several other a- 
chains, e.g. a5 forming an integrin that binds to fi- 
bronectin. The expression of the a,-chain was seen to 
increase upon PMA treatment (MFI from 41 to 72, and 
21 to 70 for THP-1 and HL-60, respectively) (Fig. 1) 
showing a very different regulation pattern for the two 
a-chains associating with the &chain. We further as- 
sayed the ability of the cytokines, TNFa, IFN-y and 
IL-l, to modify the VLA4 expression. None of the 
cytokines was able to induce a similar effect as that 
observed with PMA (not shown). 
Our findings are supported by a previous report by 
Ferreira et al. showing similar effects in another myelo- 
monocytic cell line, U937 [14]. It is also worth noting 
that the observed down-regulation is unique for the 
VLA4 molecule among the integrins involved in cell- 
cell adhesion. In addition to the up-regulation of the 
a,-chain reported here, the surface expression of both 
the a- and B-chains of the p,-integrins, LFA- 1, MAC-l 
and p150,95, are strongly up-regulated in myelomon- 
ocytic cells [15] upon PMA treatment. 
3. RESULTS AND DISCUSSION 
3.1. PMA treatment selectively decreases the surface ex- 
pression of the VLA-4 a-chain on monocytic ells 
Treatment with PMA differentiates the myelomon- 
ocytic THP-1 and HL-60 cell lines into macrophages. 
Concomitantly, a significant decrease in their VLA4 
ad-chain expression was observed (Fig. 1). The down- 
regulation of the ad-chain was dose dependent and was 
THP-1 
a4 
3.2. The decrease of a, surface expression by PMA 
treatment is not a common feature of all VLA-I- 
expressing cells 
We next analyzed whether the above-mentioned al- 
terations in the VLA4 expression pattern could also be 
HL-60 
PI a4 
Fig. 1. PMA treatment mod&s VLA-4 a- and B-chain expression of myelomonocytic THP-1 and HL-60 cells. Cells were treated with 5 nM PMA 
for 72 h and were assayed by flow cytometry using either no antibody (NIL) or specitic anti-p,, anti-a, or anti-a, antibodies and FITC-conjugated 
goat anti-mouse antibody as secondary antibody. One representative experiment out of three is presented. 
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5 nM PMA 
Fig. 2. WA-4 regulation of an osteosarcoma oell iiue HOS and a T lymphcyte line MOLT4 Cells were treated with 5 nM PMA far 72 h and 
anaIyzed by Bow cytometry as described above. NIL = secondary antibody only. One representative experiment out of four is presented. 
induced in other VLA-4-expressing cell hues, The ex- 
pression of a,- and &chains on a T cell line, MOLT+ 
slightly increased uring PMA stimulation compared to 
untreated cells. HOS is a human osteosarcoma cell line 
expressing VLA4, and PMA induction slightly in- 
creased the a, expression (from MFI 26 to 42). At the 
same time no alterations could be demonstrated in the 
/& expression of HOS cells (Fig. 2). 
These data indicate that the down-regulation of 
VLA-4 a-chain upon activation described above is not 
a generaI phenomenon for all VLA4expressing cells. 
However, although peripheral I3 lymphocytes strongly 
express ol,, a decrease in then uJ expression has been 
reported after 3 day treatment with PMA. Meanwhile 
tonsillar lymphocytes express only minor amounts of 
VLA4, but after a 3 day PMA stimulation their VLA-4 
expression is induced [15]. VLA4 expression has been 
shown to increase during T cell development. Virgin T 
cells express only low amounts of VLA4, whereas 
memory T cells are strongly VLA-4 positive [ 16,177. 
Long-term activation with lectins has been shown to 
increase VLA-4 expression on T cells [ 1 g]. 
3.3. R~~~~~~~~ of VLA-I eq.wdm at the RNA Eevd 
The changes in the expression pattern of both the a- 
and p-chains of VLA-4 require a relatively loug-term 
treatment, suggesting that these modifications take 
place both at the RNA and protein synthesis level. To 
verify this we isolated total RNA from THP-1 cells 
treated with 5 nM PMA for 24 and 48 h and analyzed 
the amount of a4 and /I, transcripts by Northern blot 
hybridization. As shown in Fig. 3, the decrease in the 
level of u4 transcripts can already be seen at 24 h of 
PMA stimulation, As previously demonstrated, the a4 
probing yields two distinct RNA bands [19], both of 
which decreased on PMA treatment. Concomitantly a 
clear increase in the amount of /I, transcript was ob- 
served, correlating to the increased total protein levels. 
3.4. Down-regulation ofa, expression leads to a decrease 
in the binding of the cells to VCAM-I 
To amwer whether the decreased expression of VLA- 
4 correlates with VCAM-1 adhesion we assessed the 
binding of the cells to the recombinant soluble purified 
VCAM-1 protein. Non-stimulated THP-1 cells adhered 
strongly to the VCAM-l-coated surfaces (Fig. 4). This 
adhesion was selective since pretreatment of the cells 
with ant&x4 or the pretreatment of rsVCAM-l-coated 
plates with anti-VCAM-1 monoclonal antibody 
blocked the cell adhesion, whereas non-relevant anti- 
bodies had no effect. Binding to BSA-treated control 
was maximally 5% of the VCAM-I binding. Down- 
regulation of the a&-ohain by PMA treatment led to a 
nearly IO-fold decrease in the capacity of THP-1 cells 
to adhere to VCAM- 1 -coated surfaces (average number 
of cells adhered per one microscopic field decreased 
from 590 f 50 to 63 f 10, P < 0.0001 in Student’s t-test, 
Fig. 3). The remaining binding appeared to be VLA-4/ 
VCAM-1 specific, since it could be further diminished 
to basal level by anti-VCAM-1 and anti-VLA-4 anti- 
body treatments. Again no effect was observed with 
irrelevant antibodies. 
Classically the regulation of integrin-mediated leuko- 
cyte binding to endothelial cells is believed to be mgu- 
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increase in their VLA-4 surface expression. Surpris- 
ingly, however, the same treatment of peripheral B lym- 
phocytes led to a similar increase in binding, although 
simultaneously the VLA-4 expression was seen to de- 
crease [15]. This is the first time that the down-regula- 
tion instead of up-regulation of VLA4 has correlated 
to VCAM-1 binding. In the report of Ferreira et al., 
similar changes in U937 a$, and CX& were linked to 
an enhanced binding to fibronectin, whereas the effect 









Chid PMAZ4li PMA48h 
Fig. 3. The effect of PMA on THP-1 VLA-4 d- and p-chain RNA 
levels. Total RNA was isolated from untreated THP-1 cells and cells 
treated with 5 nM PMA for 24 and 48 h. The amount of a- and/I-chain 
RNA was quantified by Northern blot analysis and the amount of 
RNA was normalized to actin RNA. (A) The a-chain probe detects 
two bands, both of which decrease during PMA treatment. (B) PMA 
treatment increased the RNA expression of the @ham. (C) Relative 
scanning values for both a-chains (named a4 up and a4 low) and the 
/?-chain. 
lated by modifying (i) the avidity of the integrin, and (ii) 
the amount of its endothelial counterpart. This view is 
supported by studies showing that the amount of VLA- 
4 expressed on the cell surface is not directly linked to 
its ability to adhere. For instance, even though periph- 
eral B cells are VLA4 positive they do not adhere to 
fibronectin. However, the avidity of VLA-4 to bind fi- 
bronectin can be increased by a short-term PMA stimu- 
lation 1151. The avidity of leukocytic VLA-4 can also be 
increased by treating the cells with a monoclonal anti- 
&integrin antibody (8A2) 1201. However, some reports 
linking quantitative up-regulation of VLA4 to en- 
hanced binding also exist. Although a short-term PMA 
stimulation increases the avidity of VLA-4 on T cells, 
their fibronectin binding is also enhanced when T cells 
are differentiated and concomitantly increase their 
VLA4 expression [16]. Also, a 3 day PMA treatment 
of tonsillar lymphocytes has been shown to dramati- 
cally enhance their adherence to fibronectin due to an 
Only very little information is available on the regula- 
tion of VLA-4 expression in vivo. Previous studies have 
shown that the VLA-4~CAM-1 interaction is essential 
in inflammatory reactions as well as in embryonic devel- 
opment. Recently, the VLA-4NCAM-1 interaction was 
shown to play a role in myogenesis [21], linking for the 
first time this interaction to the events of tissue develop- 
ment. Increased VLA4 expression has, on the other 
hand, been shown to be associated with some diseases. 
T cells isolated from peripheral blood and affected syn- 
ovias from patients with rheumatic arthritis expressed 
more VLA-4 than those isolated from healthy donors 
[22]. In addition to these hematopoeti~ cells, VLA-4 is 
also expressed on some non-hematopoeti~ malignant 
cells, like sarcomas and melanomas, but not on their 
benign counterparts [5,23-251. These findings suggest 
that the regulation of VLA-4/VCAM-1 interaction is 
putatively important during metastatic spread of these 
cells. On the other hand in a rabbit model the VCAM- 
1NLA4-mediated binding has been shown to play a 
role in the formation of atherosclerotic plaques [26]. 
Being able to down-regulate the VLA-4/VCAM-1 in- 
teraction might have applications in treating or prevent- 
Control 
+ anti VCAM-1 
+ anti VLA-4 
5 nM PMA 
+anti VCAM-1 
+ anti VLA-4 
Celts adhered 
Fig. 4. The effect of PMA on THP-1 binding to rsVCAM-1 tIxed on 
microtiter plates. Non-treated THP-1 cells or celis treated with anti- 
CD1 8 antibody bound avidly to the rsVCAM-1 coated plates, whereas 
there was practically no binding to BSA-coated control wells (data not 
shown). The observed binding was VLA-4 and VCAM-1 dependent, 
since both the anti-VLA-4 u-chain (CD49d) and anti-VCAM-1 mono- 
clonal antibodies abolished it. PMA treatment (5 nM, 72 h) dramati- 
cally decreased the VLA-4/VCAM-l-dependent binding of THP-1 
cells to rsVCAM-1. One representative xperiment out of five is 
shown. Note the logarithmic horizontal axis. 
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ing diseases that involve cell-to-cell adhesion via this 
interaction, and this might have applications in anti- 
inflammatory, -arteriosclerosis and -metastatic ap- 
proaches. 
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